China's cervical cancer trends show national stabilization but reveal concerning disparities that threaten global elimination efforts, according to recent research published in Cancer Biology & Medicine. While overall incidence and mortality rates have plateaued since 2016, older women and those in rural areas continue to face increasing risks, highlighting urgent equity challenges in the country's prevention strategies.
The study analyzed two decades of data from 22 cancer registries across China, revealing that age-standardized incidence rates tripled from approximately 3 per 100,000 women in 2000 to over 10 per 100,000 by 2016. This dramatic increase, averaging 6.5% annually, was followed by national stabilization after 2016. However, beneath this overall trend lies significant demographic divergence that complicates China's path toward cervical cancer elimination.
Urban women under 35 years old have experienced declining incidence rates since 2009, likely due to improved screening access and awareness. In contrast, rural women aged 35-64 continue to face increasing incidence, while women aged 65 and older show steadily rising rates in both urban and rural areas. These disparities reflect uneven access to prevention services across China's vast population.
When compared internationally, China's progress lags significantly behind countries like Australia and the Republic of Korea, where integrated human papillomavirus vaccination and screening programs have produced consistent declines in cervical cancer rates. The research, available at https://doi.org/10.20892/j.issn.2095-3941.2025.0386, used Joinpoint regression analysis to identify these critical patterns.
The implications extend beyond China's borders, as the country accounts for nearly one-fifth of the world's female population. Current prevention efforts face substantial coverage gaps, with only about half of women aged 35-64 receiving screening and less than 10% of girls completing HPV vaccination. These limitations particularly affect rural and aging populations, creating barriers to achieving the World Health Organization's elimination targets.
Professor Wenqiang Wei, corresponding author of the study, emphasized that China's stabilization represents a critical inflection point but warned against complacency. The continuing age and regional disparities demand urgent policy recalibration to ensure equitable access to vaccination, screening, and timely treatment across all demographic groups.
Researchers recommend expanding school-based HPV vaccination programs, scaling up primary HPV testing with self-sampling options, and ensuring standardized treatment across healthcare levels. Integration of artificial intelligence-assisted cytology and digital registries could further improve early detection capabilities. As China approaches its projected peak cervical cancer burden around 2040, strengthening coordination between public health programs and local governments will be vital for narrowing the urban-rural gap and making elimination achievable.
